Skip to main content

Table 3 Comparison of three designs for (p0, p1, α, β) = (0.05, 0.2, 0.1, 0.1) based on practical example

From: Optimal, minimax and admissible two-stage design for phase II oncology clinical trials

 n1a1r1PET1nrENTypeq
Simon’s design1200.54037323.5Optimal[0.000, 0.091]
1300.51335323.7Admissible[0.091, 0.333]
1400.48834324.3Inadmissible
1500.46333324.7Admissible[0.333, 0.630]
1800.39732326.4Minimax[0.630, 1.000]
Fleming’s design12030.56037423.0Optimal[0.000, 0.091]
13030.53835423.2Admissible[0.091, 0.268]
16030.48332424.3Admissible[0.268, 0.444]
18030.45531425.1Minimax[0.444, 1.000]
  1. n1 and n is the sample size required in the first stage and in the whole trial, respectively. (a1, r1, r) are the critical values. PET1 denotes the probability of early termination in the first stage. EN represents expected sample size